|
|
|
|
|
|
|
|
|
Sterile Fill/Finish Capability
|
Upperton’s 7,000 sq ft sterile manufacturing facility is MHRA approved against Annex 1 guidelines and delivers flexible fill/finish solutions for aseptic and terminally sterilised products. Supporting parenteral, ocular and pulmonary drug products, our expertise spans small molecules, biologics, peptides and monoclonal antibodies. Equipped with advanced VHP isolator technology and designed to stringent Annex 1 standards, we provide formulation development, sterile processing, vial and pre-filled syringe filling, and sterility assurance to accelerate clinical and commercial success. Learn more.
|
|
|
|
|
|
|
|
The 3 Cs You Should Expect From Your Pharma Services Provider
|
|
White Paper | By Yves Massicotte, Ropack Pharma Solutions
|
We share important factors to consider when weighing your contract service provider options. These “Three Cs” can indicate whether a service provider has the capabilities desired by a drug sponsor.
|
|
|
|
|
|
Mitigating Powder Flow And Static Issues
|
|
Case Study | Grace Fine Chemical Manufacturing Services
|
See how incorporating small amounts of mesoporous silica during micronization can significantly enhance powder flow, thereby making subsequent blending and formulation more efficient.
|
|
|
|
|
|
A Powerful Non-Destructive Tool For Tablet Characterization
|
|
White Paper | By Rahul V. Haware, Robert Sedlock, Grant Sedlock, et al., Natoli Engineering Company, Inc.
|
Discover how X-ray micro-CT provides vital, non-destructive analysis of a tablet’s internal 3D physical structure. This structural insight is essential for troubleshooting defects and confirming performance.
|
|
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma
|
There’s something sadly predictable about negative media reaction to a woman whose professional accomplishments ought to command attention before anything else, writes Chief Editor Louis Garguilo. "But what interests others heading into the Heidi Overton nomination process for FDA Commissioner is whether she can guide the FDA to help us get medicines developed, manufactured, and approved. So what kind of FDA does the outsourcing supply chain need?"
|
|
|
|
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
|
|
|
|
Is My Molecule Suitable For An Orally Disintegrating Tablet?
|
|
White Paper | By Susan Banbury, Adina Dîrlea, Charli Smardon, et al., Catalent
|
Innovations in drug delivery formats are enabling more patient-centric treatments and helping to boost patient compliance. Learn about the advances being developed to expand ODT technology.
|
|
|
|
|
|
|
|
|
|
AI Innovation in Drug Development & Manufacturing | Sept. 29, 2026
|
This session explores why AI adoption in drug manufacturing is often limited by poor data quality rather than technology. Attendees will learn how improved data governance, standardized formats, and real-time monitoring can enhance AI-driven insights, product quality, and operational efficiency. Designed for pharma and biotech CMC, engineering, operations, and safety professionals, it highlights current AI success stories and key foundations for scaling AI initiatives. Learn more.
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
